Explore original articles, case reports, and podcasts that focus on psoriasis.
Efficacy and Safety of Systemic Treatments for Skin and Joint Manifestations in Patients With Psoriasis
March 2020 | Volume 19 | Issue 3 | Original Article | 306 | Copyright © March 2020
Psoriasis is a chronic, systemic disease with features suggestive of autoimmune dysregulation. Patients with psoriasis vulgaris frequently experience systemic comorbidities, including cardiovascular a...
Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy
August 2019 | Volume 18 | Issue 8 | Original Article | 815 | Copyright © August 2019
Background: Psoriasis is a chronic, immune-mediated disease that varies widely in its clinical expression. Topical corticosteroids (TCS) are the mainstay of treatment. Long-term safet...
Efficacy of Dupilumab in Different Racial Subgroups of Adults With Moderate-to-Severe Atopic Dermatitis in Three Randomized, Placebo-Controlled Phase 3 Trials
August 2019 | Volume 18 | Issue 8 | Original Article | 804 | Copyright © August 2019
Dupilumab, a monoclonal antibody that blocks the shared receptor subunit for interleukin (IL)-4 and IL-13, is currently approved for the treatment of adults with inadequately controlled moderate-to-se...
August 2019 | Volume 18 | Issue 8 | Original Article | 798 | Copyright © August 2019
Cutaneous fungal infections account for millions of office visits per year, yet their varied presentations often lead to misdiagnosis. If dermatology clinics are Clinical Laboratory Improvement Amendm...
Two Multicenter, Randomized, Double-Blind, Parallel Group Comparison Studies of a Novel Foam Formulation of Halobetasol Propionate, 0.05% vs Its Vehicle in Adult Subjects With Plaque Psoriasis
August 2019 | Volume 18 | Issue 8 | Original Article | 790 | Copyright © August 2019
Background: A novel foam formulation of halobetasol propionate, 0.05% (HBP-Foam) has been developed to treat plaque psoriasis in patients who prefer a thermostable topical foam with l...
Comparison of the Safety and Efficacy of Tumor Necrosis Factor Inhibitors and Interleukin-17 Inhibitors in Patients With Psoriasis
August 2019 | Volume 18 | Issue 8 | Original Article | 776 | Copyright © August 2019
Psoriasis (PsO) is a common, systemic, chronic inflammatory disease characterized by key clinical symptoms, including itching, pain, and scaling, and is associated with substantial physical, psychosoc...
August 2019 | Volume 18 | Issue 8 | Original Article | 756 | Copyright © August 2019
Background: Topical corticosteroids are efficacious treatment options for multiple dermatoses. However, ointments and cream corticosteroid vehicles can be cumbersome to patients and m...
Prescribing Patterns Associated With Biologic Therapies for Psoriasis from a United States Medical Records Database
August 2019 | Volume 18 | Issue 8 | Original Article | 745 | Copyright © August 2019
Introduction: Selecting a systemic therapy for patients with psoriasis is a complex process, based on a variety of factors including psoriasis severity, comorbid health conditions, ac...
Combination Use of Systemic Therapies in Psoriasis: Baseline Characteristics from the Corrona Psoriasis Registry
August 2019 | Volume 18 | Issue 8 | Original Article | 731 | Copyright © August 2019
Importance: There are increasing options for systemic combination therapy for psoriasis but a lack of literature around the characteristics of patients who are started on these regime...
August 2019 | Volume 18 | Issue 8 | Original Article | 718 | Copyright © August 2019
Melasma and postinflammatory hyperpigmentation (PIH) are the most common forms of dyschromia in patients with skin of color. Both are associated with a high psychological burden of disease. To exacerb...
August 2019 | Volume 18 | Issue 8 | Case Reports | 217 | Copyright © August 2019
Psoriasis is a common dermatologic condition with a variety of morphologic presentations. These variations include the less common hyperkeratotic form, psoriasis ostracea, defined as having pronounced...
August 2019 | Volume 18 | Issue 8 | Case Reports | 218 | Copyright © August 2019
A 56-year-old Caucasian male with a history of chronic plaque psoriasis, primary sclerosing cholangitis status-post liver transplant on tacrolimus, and ulcerative colitis on infliximab developed a pro...
A Double-Blind Randomized Pilot Study Evaluating the Safety and Efficacy of Topical MEP in the Facial Appearance Improvement of Estrogen Deficient Females
November 2018 | Volume 17 | Issue 11 | Original Article | 1186 | Copyright © November 2018
Facial skin aging is accelerated in postmenopausal females due to decreased collagen, reduced hydration, and loss of skin elasticity constituting the characteristics of estrogen deficient skin (EDS). ...
August 2018 | Volume 17 | Issue 8 | Department | 27 | Copyright © August 2018
Research into the immunopathological mechanisms of plaque psoriasis has produced increasingly targeted biologic therapies. The specificity of these agents allows for high rates of efficacy and decreas...
Rapid Onset of Action in Patients With Moderate-to-Severe Plaque Psoriasis With Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination
August 2018 | Volume 17 | Issue 8 | Original Article | 863 | Copyright © August 2018
Background: Psoriasis is a chronic condition often managed with topical therapy. Patients have high expectations about the speed at which improvement is achieved, which then can have a marked impact o...
Safety and Efficacy of a Fixed Combination Halobetasol and Tazarotene Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Pooled Analysis of Two Phase 3 Studies
August 2018 | Volume 17 | Issue 8 | Original Article | 855 | Copyright © August 2018
Background: Topical corticosteroids (TCS) are the mainstay of psoriasis treatment. Safety concerns may limit use. Combination with tazarotene may optimize efficacy and minimize safety and tolerability...
August 2018 | Volume 17 | Issue 8 | Original Article | 835 | Copyright © August 2018
Psoriasis is a chronic, systemic, inflammatory disease with manifestations resulting from a dysregulated immune response. In psoriatic skin, expression of all phosphodiesterase 4 (PDE4) isoforms (A-D)...
Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years
August 2018 | Volume 17 | Issue 8 | Original Article | 826 | Copyright © August 2018
Background: Due to the chronic nature of psoriasis, it is important to assess the sustained response of treatments over time. Objective: To assess the efficacy of continuous treatment with guselkumab...
March 2018 | Volume 17 | Issue 3 | Original Article | 247 | Copyright © March 2018
BACKGROUND: The advent of biologics has improved patient outcomes in the treatment of moderate-to-severe psoriasis. The time it takes for patients to see clinically meaningful improvement is an import...
Efficacy and Safety of Apremilast in Systemic- and Biologic-Naive Patients With Moderate Plaque Psoriasis: 52-Week Results of UNVEIL
February 2018 | Volume 17 | Issue 2 | Original Article | 221 | Copyright © February 2018
BACKGROUND: Many patients with moderate plaque psoriasis are undertreated despite broadening treatment options. In the phase IV UNVEIL study, oral apremilast demonstrated efficacy and safety in sys...